Quarterly report pursuant to Section 13 or 15(d)

Notes Payable

v3.6.0.2
Notes Payable
9 Months Ended
Dec. 31, 2016
Notes to Financial Statements  
Notes Payable

The following table summarizes our unsecured promissory notes at December 31, 2016 and March 31, 2016.

 

    December 31, 2016     March 31, 2016  
    Principal     Accrued           Principal     Accrued        
    Balance     Interest     Total     Balance     Interest     Total  
                                     
   5.75% Note payable to insurance premium                                    
financing company (current)   $ 35,800     $ -     $ 35,800     $ -     $ -     $ -  
                                                 
                                                 
  7.0% Note payable to Progressive Medical Research   $ -     $ -     $ -     $ 58,800     $ 12,000     $ 70,800  
 less: current portion     -       -       -       (31,600 )     (12,000 )     (43,600 )
  7.0% Notes payable - non-current portion   $ -     $ -     $ -     $ 27,200     $ -     $ 27,200  
                                                 
  Total notes payable to unrelated parties   $ 35,800     $ -     $ 35,800     $ 58,800     $ 12,000     $ 70,800  
 less: current portion     (35,800 )     -       (35,800 )     (31,600 )     (12,000 )     (43,600 )
Net non-current portion   $ -     $ -     $ -     $ 27,200     $ -     $ 27,200  

 

Between May 2015 and August 2015, we extinguished the outstanding balances of approximately $17,200,000 of indebtedness, including all senior secured promissory notes and a substantial portion of other indebtedness that was either due and payable or would have become due and payable prior to March 31, 2016, by converting such indebtedness into shares of our Series B Preferred at a Conversion Price (or stated value) of $7.00 per share.

 

Evaluating each converted note or debt class separately, we determined that the conversion of each of such notes and other debt instruments into Series B Preferred should be accounted for as an extinguishment of debt. Because the fair value of the Series B Preferred into which the debt instruments were converted in all cases exceeded the carrying value of the debt, we recorded an aggregate, non-recurring, non-cash loss on extinguishment of debt of $26,700,200, in our fiscal year ended March 31, 2016, as reflected in the accompanying Condensed Consolidated Statement of Operations and Comprehensive Loss for the nine months ended December 31, 2015.

 

On January 5, 2016, we paid in full the $33,300 outstanding balance (principal and accrued but unpaid interest) of the promissory note previously issued to the University of California in connection with our collaborative research and development relationship with the University of California at Davis.

 

On June 13, 2016, we paid in full the $71,600 outstanding balance (principal and accrued but unpaid interest) of the promissory note we issued to Progressive Medical Research (PMR) in connection with our clinical development relationship with PMR.

 

In May 2016, we executed a promissory note in the face amount of $117,500 in connection with certain insurance policy premiums. The note is payable in monthly installments of $12,100, including principal and interest, through March 2017, and the remaining balance of such note as of December 31, 2016 was $35,800.